WASHINGTON — Moderna’s COVID-19 vaccine is the simplest at protecting towards COVID-19 hospitalizations, in accordance with a research revealed Friday by the Centers for Illness Control and Prevention.
An analysis of greater than three,600 adults hospitalized at 21 U.S. amenities from March to August discovered that vaccine efficacy towards hospitalization was 93 % for the Moderna vaccine in comparison with 88 % for the BioNTech/Pfizer shot.
The effectiveness of the BioNTech/Pfizer vaccine declined considerably after 120 days, the CDC’s report stated, though it still offered robust safety towards severe disease.
The Moderna vaccine also produced greater post-vaccination antibody ranges than the BioNTech/Pfizer vaccine, the research found.
The CDC has released several research taking a look at vaccine efficacy particularly teams, reminiscent of frontline well being care staff, because the administration prepares to roll out boosters to a minimum of some adults within the coming weeks. While some of these research have included knowledge on efficacy of the varied vaccines, the research revealed Friday presents larger perception into the extent to which Moderna, BioNTech/Pfizer and Johnson & Johnson shield towards severe disease and COVID-19 hospitalization.
The info from the current CDC cohort research suggests that the two-dose Moderna and BioNTech/Pfizer vaccine regimens shield higher towards hospitalization than the single-dose Johnson & Johnson shot. Nevertheless, the Johnson & Johnson vaccine still decreased danger of COVID-19-related hospitalization by 71 %.
Although the efficacy of the vaccines assorted, the CDC research showed that all the FDA-approved COVID-19 vaccines still work properly at defending towards COVID-19 hospitalization.